Mainz Biomed NV F-1 registration statements

Mainz Biomed N.V. is undertaking a best-efforts public offering of up to 1,470,588 ordinary and pre-funded units to raise approximately $2.565 million net, aiming to advance its colorectal and pancreatic cancer screening tests despite ongoing operating losses and significant shareholder dilution.

Mainz Biomed N.V. is planning a best-efforts offering of ordinary units and pre-funded units to raise capital for its eAArly Detect 2 study, product development, commercial expansion, and debt repayment.

Mainz Biomed N.V. plans to offer ordinary and pre-funded units, aiming to raise capital for clinical studies, product development, and commercial expansion.

Mainz Biomed N.V. is conducting a best-efforts offering of ordinary and pre-funded units to raise capital for its cancer detection technology development and commercialization.

Mainz Biomed has filed an amendment to its Form F-1 registration statement, primarily to include an updated legal opinion and revised exhibit list.

Mainz Biomed N.V. has filed an amendment to its registration statement for a proposed offering of up to $8 million in ordinary and pre-funded units, including warrants.

Mainz Biomed N.V. announces a best-efforts offering of ordinary shares and pre-funded warrants to raise capital for clinical studies, product development, and debt repayment.